DaVita Inc. vs Tenet Healthcare Corporation: Strategic Comparison

This in-depth comparison examines DaVita Inc. and Tenet Healthcare Corporation across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching DaVita Inc. on its own, evaluating Tenet Healthcare Corporation, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between DaVita Inc. and Tenet Healthcare Corporation is widest.

On the headline numbers, DaVita Inc. reports annual revenue of $13.6B against $21.3B for Tenet Healthcare Corporation, while their respective market capitalizations stand at $12.4B and $17.2B. DaVita Inc. is headquartered in United States and Tenet Healthcare Corporation operates from United States, and those different home markets shape how each company competes.

DaVita Inc.: DaVita is a Denver-based kidney care provider and a member of the S&P 500. It offers in-center hemodialysis, home peritoneal dialysis and home hemodialysis, hospital inpatient dialysis, and care management for chronic kidney disease. At June 30, 2026 it served about 298,500 patients at 3,266 outpatient centers worldwide. CEO Javier J. Rodriguez has led the company since 2019, and Berkshire Hathaway, its largest shareholder since first buying in 2011, owns about 45%.

Tenet Healthcare Corporation: Tenet Healthcare's official story is about 50 acute care hospitals and more than 500 ambulatory surgery centers generating $20.68 billion in fiscal 2024 revenue. The real story is more specific: a company that inherited the wreckage of Oral Roberts' failed $80 million City of Faith medical center, survived a $900 million Medicare fraud settlement in 2006, and has since rebuilt itself into a business whose most valuable asset is a revenue cycle management subsidiary most people have never heard of. The 99,000 employees spread across 30 states handle 4.2 million inpatient admissions annually. That is the visible operation. The less visible operation is Conifer Health Solutions, a revenue cycle management subsidiary that reduced internal days in accounts receivable to 48 days in fiscal 2024, meaningfully below the industry average of 54 days, by deploying AI-driven patient engagement software that processes claims faster than competitors' systems. The hospital segment achieved a 12.8% adjusted EBITDA margin in fiscal 2024, which management directly attributed to cutting contract labor costs by 45% compared to the fiscal 2022 peak. The travel nurse crisis that inflated labor costs across the industry hit Tenet hard, the company's response was to invest in permanent staffing infrastructure rather than continue paying premium rates to temporary contract workers. Revenue has grown from $19.1 billion in fiscal 2022 to $20.68 billion in fiscal 2024, a steady increase that reflects both the ambulatory surgery center expansion and the USPI segment's 6.5% same-facility revenue growth driven by high-acuity orthopedic and gastroenterology procedures. The company has also retired more than $4 billion in debt since 2020, reducing its leverage ratio to 2.1x.

DaVita Inc. and Tenet Healthcare Corporation pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between DaVita Inc. and Tenet Healthcare Corporation.

DaVita Inc. business model: DaVita is paid per dialysis treatment. Most patients receive in-center hemodialysis about three times a week, while others dialyze at home with DaVita training and support. Medicare's bundled ESRD payment covers the majority of patients, but commercial insurers pay substantially more per treatment, so payer mix is the key profit driver. In Q2 2026 U.S. revenue per treatment was $415.87 against patient care costs of $277.40. Many clinics are joint ventures with nephrology practices, and the Integrated Kidney Care (IKC) unit takes risk-based contracts, including the CMS Kidney Care Choices model, where DaVita shares in savings when total cost of care falls.

Tenet Healthcare Corporation business model: Conifer's business model is scalable, relying on a combination of long-term, multi-year enterprise contracts, performance-based fee structures (where Conifer takes a percentage of the additional revenue it recovers for the client), and the licensing of its proprietary analytics and patient engagement software platforms. Every 1% increase in the company's reliance on contract labor translates to tens of millions of dollars in incremental annualized expense, a cost that cannot be immediately passed through to fixed-fee Medicare reimbursement rates or fully recovered in commercial payer negotiations that are locked into multi-year contracts. Finally, the macroeconomic environment of elevated interest rates has significantly increased the cost of refinancing Tenet's substantial long-term debt load, meaning that even as the company pays down principal, the interest expense associated with its remaining variable-rate facilities and upcoming maturities continues to consume a significant portion of its operating cash flow, restricting the capital available for dividend payments, share buybacks, or aggressive M&A expansion in the fragmented ASC market. The company's geographic footprint provides a third layer of competitive defense, as Tenet has concentrated its hospital and ASC assets in high-growth, high-managed-care-penetration markets in the Sun Belt, specifically Florida, Texas, Arizona, and the Carolinas, where demographic tailwinds, favorable regulatory environments, and a concentration of commercially insured patients provide a structural pricing advantage over competitors burdened by legacy facilities in declining, unionized, or Medicaid-dominant markets in the Northeast and Midwest. Concurrently Tenet is betting on the transition from fee-for-service reimbursement to value-based care contracts, using its Conifer Health Solutions analytics platform and its network of employed and affiliated physicians to build the population health management infrastructure required to assume downside financial risk for the total cost of care for millions of Medicare Advantage and commercially insured lives.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of DaVita Inc. stack up against those of Tenet Healthcare Corporation.

DaVita Inc. competitive advantage: DaVita's advantages are scale and operating discipline. Its dense U.S. network of 2,671 clinics, long-standing nephrologist joint ventures, purchasing scale, and experience with Medicare billing and quality programs are hard for new entrants to copy. Recurring treatment schedules create predictable demand, which supports steady free cash flow ($1.024 billion in 2025) and large share buybacks.

Tenet Healthcare Corporation competitive advantage: The sheer scale of Tenet's operational footprint, comprising about 50 acute care hospitals, 275 urgent care and occupational health centers, and more than 500 ambulatory surgery centers, means that on any given day, the company is simultaneously negotiating reimbursement rates with dozens of major commercial insurers, managing the clinical outcomes of hundreds of thousands of acute care patients, and processing millions of medical claims through its internal revenue cycle engine. This labor cost inflation is occurring simultaneously with a severe deterioration in the commercial payer mix across several of Tenet's key urban markets, as Medicaid enrollment surges following the unwinding of the pandemic-era continuous coverage provision, and as Medicare Advantage plans use prior authorization and denial tactics to shift financial risk back onto the hospitals. Tenet's competitive advantage is fortified by the proprietary, scale-driven data analytics and operational playbooks developed by its Conifer Health Solutions subsidiary, which processes billions of dollars in claims annually and has engineered a revenue cycle management engine that consistently outperforms industry benchmarks in days in accounts receivable and clean claim rates. This internal expertise not only protects Tenet's own hospital margins from the increasingly aggressive denial management tactics of commercial payers but also creates a sticky, high-margin B2B service that external health systems rely upon, creating significant switching costs for third-party clients. This merger, orchestrated by Tenet then-CEO Jeffrey Barbakow, was a classic 1990s healthcare consolidation play, driven by the belief that scale was required to negotiate favorable managed care contracts with the rapidly growing dominance of HMOs and PPOs.

Future prospects matter as much as current results. The growth strategies below explain how DaVita Inc. and Tenet Healthcare Corporation each plan to expand from here.

DaVita Inc. growth strategy: DaVita's strategy is to grow earnings faster than revenue. It raises revenue per treatment, controls patient care costs, and buys back shares with free cash flow. It also expands international clinics (595 centers in 14 countries by mid-2026), grows home dialysis, and scales Integrated Kidney Care risk contracts that pay for slowing disease progression and reducing hospitalizations. Through Mozarc Medical, its kidney-technology joint venture with Medtronic, it invests in new dialysis devices.

Tenet Healthcare Corporation growth strategy: The company's strategic thesis rests on the premise that the American healthcare system will continue its inexorable shift toward value-based care and outpatient procedures, a transition Tenet is actively engineering through its United Surgical Partners International (USPI) joint ventures, which now account for a rapidly growing percentage of the company's total EBITDA. Tenet's strategic focus is on markets with favorable demographic trends, high managed care penetration, and strong commercial payer mix, allowing it to negotiate favorable reimbursement contracts. The company has undergone a financial transformation over the past decade, shifting from a leveraged, acquisition-heavy growth model to a disciplined, cash-generative operator focused on debt reduction, margin expansion, and outpatient growth. Under CEO Saum Sutaria, Tenet has stabilized its clinical workforce, optimized its real estate footprint, and expanded its USPI platform to capture the secular shift toward outpatient procedures. Despite facing ongoing industry headwinds such as labor cost inflation, uncompensated care, and regulatory scrutiny, Tenet's diversified revenue streams and strategic positioning in high-growth markets have enabled it to deliver consistent financial performance and restore its balance sheet to investment-grade stability. The company's strategy in this segment is not to maximize the sheer number of beds, but to optimize the acuity of the patients admitted, actively shedding low-margin, high-volume Medicaid patients in certain markets while investing in specialized service lines like cardiology, neuroscience, and oncology that attract higher-paying commercial and Medicare Advantage patients. The second pillar of Tenet's revenue model is United Surgical Partners International (USPI), the company's ambulatory surgery center (ASC) and surgical hospital joint venture platform, which accounts for approximately 10% of total revenue but contributes a disproportionately higher percentage of total company EBITDA due to its significantly lower overhead costs and higher operating margins. This joint-venture structure is the critical mechanical advantage of the USPI model: by giving referring physicians an ownership stake in the surgery center, Tenet aligns the financial incentives of the doctors with the operational success of the facility, ensuring a steady, predictable stream of patient referrals while simultaneously reducing the capital expenditure required to build or acquire new centers. Tenet's strategy here is aggressive expansion through de novo development (building new centers from scratch) and strategic acquisitions of independent ASCs, followed by the integration of these centers into its existing joint-venture network to capture economies of scale in purchasing, IT infrastructure, and managed care contracting. The Hospital Operations segment provides the patient volume and clinical prestige necessary to attract top-tier physician partners. Those physician partners, in turn, are invited to co-invest in USPI ambulatory surgery centers, ensuring that as their patients require outpatient procedures, those procedures are performed within the Tenet network rather than at a competitor's facility. Tenet's future growth is entirely dependent on its ability to execute its aggressive outpatient expansion strategy, targeting the addition of 40 to 50 new ambulatory surgery centers annually and the continuous external monetization of its Conifer RCM platform, as the company explicitly bets on the irreversible macroeconomic shift of complex surgical procedures migrating out of the traditional inpatient hospital setting and into lower-cost, higher-margin outpatient environments. However, the most dangerous competitive threat to Tenet's long-term growth trajectory is not another traditional hospital operator, but the well-capitalized private equity firms and specialized ambulatory surgery platforms, such as Envision Healthcare, AmSurg (now part of Envision), and SurgCenter Development, that are consolidating the fragmented ASC market. These PE-backed platforms possess lower cost structures, faster decision-making cycles, and the ability to offer physicians lucrative equity rollovers and dividend recapitalizations, forcing Tenet's USPI platform to continuously innovate its joint-venture terms and operational support to retain its physician partners and win new de novo developments. To survive and thrive in this hyper-competitive environment, Tenet has been forced to execute a strategy of hard-nosed geographic optimization, systematically selling or closing underperforming hospitals in competitive, low-margin markets (such as the divestiture of its Detroit Medical Center and numerous California facilities) and reinvesting the proceeds into expanding its USPI ambulatory surgery footprint and acquiring specialty hospitals in high-growth Sun Belt markets where it can achieve dominant market share and favorable payer mix. The financial narrative of Tenet Healthcare in FY2024 is one of a company that has navigated the most severe labor and inflationary shock in the history of the American hospital industry, emerging with a streamlined, optimized operational footprint, a profitable and rapidly growing outpatient platform, and a balance sheet that is finally providing the financial flexibility required to compete in the next phase of healthcare industry consolidation. Tenet faces intense, existential competitive pressure from HCA Healthcare, the national leader in for-profit hospital operations, which possesses superior scale, pricing power, and capital allocation efficiency, allowing HCA to outbid Tenet for top-tier physician partners, acquire the most lucrative ambulatory surgery centers, and negotiate more favorable managed care contracts in overlapping geographic markets. The regulatory environment also presents a persistent, high-stakes challenge, as the Centers for Medicare and Medicaid Services (CMS) continues to implement aggressive audit programs, such as the Recovery Audit Contractor (RAC) initiative and the Two-Midnight Rule enforcement, which systematically scrutinize Tenet's inpatient admission decisions and frequently result in costly clawbacks of previously recognized revenue. The single, unreplicable competitive moat that Tenet Healthcare possesses, which no competitor can duplicate in under five years, is its entrenched, physician-aligned joint venture architecture within the United Surgical Partners International (USPI) platform, which structurally locks in patient referral networks through equity co-investment and shared governance. Tenet Healthcare's growth strategy for FY2025 and beyond is executed through three specific, targeted initiatives designed to shift the company's revenue mix toward higher-margin, outpatient, and technology-enabled services while systematically optimizing its legacy inpatient footprint. The first and most capital-intensive initiative is the aggressive expansion of the United Surgical Partners International (USPI) ambulatory surgery center joint venture platform, with a specific target of adding 40 to 50 new centers annually through a combination of de novo development and strategic acquisitions of independent, physician-owned ASCs. Tenet's growth engine in this segment relies on its proprietary 'Center of Excellence' model, where it partners with high-volume, top-tier physician groups to build specialized, high-acuity ASCs focused on complex orthopedics, spine, and cardiovascular procedures, leveraging Tenet's managed care contracting leverage to secure premium reimbursement rates that are unavailable to standalone, independent centers. The company is also actively pursuing the acquisition of controlling stakes in existing USPI joint ventures where its physician partners are seeking liquidity, allowing Tenet to consolidate the EBITDA of these profitable centers onto its own balance sheet and capture the full financial upside of their continued growth. The second core growth initiative is the external monetization and technological expansion of Conifer Health Solutions, with a strategic target of growing third-party RCM revenue by 10% to 12% annually through the signing of large-scale, multi-year enterprise contracts with mid-sized and regional health systems that lack the scale to build their own advanced revenue cycle infrastructure. Conifer's growth strategy involves the deployment of its proprietary 'Conifer OnCare' platform, an AI-driven patient engagement and financial clearance tool that automates prior authorizations, estimates patient financial responsibility with high accuracy, and reduces bad debt write-offs, creating a differentiated, technology-led value proposition that allows Conifer to compete against larger, more established RCM vendors like R1 RCM and Optum. The third pillar of the growth strategy is the systematic optimization and service line enhancement of the remaining Hospital Operations footprint, which involves the targeted reinvestment of capital into high-margin, high-demand specialty service lines, specifically emergency care, cardiology, neuroscience, and women's services, at Tenet's flagship hospitals in high-growth Sun Belt markets. This initiative includes the construction of new freestanding emergency departments (FSEDs) in rapidly expanding suburban corridors in Texas and Florida, which serve as high-volume patient intake funnels that drive admissions to the company's nearby acute care hospitals, and the acquisition of employed physician groups in key specialties to ensure a steady, controlled referral pipeline for the hospital's inpatient and outpatient services. The company's future growth strategy also involves the systematic optimization of its remaining inpatient hospital footprint, which will see continued divestitures of low-margin, rural, or competitive facilities, and the reinvestment of those proceeds into specialized, high-acuity service lines such as neuroscience, cardiovascular care, and oncology at its remaining flagship hospitals, ensuring that the inpatient network serves as a high-prestige referral engine for the most complex cases while the USPI network captures the bulk of the profitable, routine surgical volume. However, the newly formed Tenet inherited a toxic combination of aging, inefficient hospital assets, a leveraged balance sheet, and a flawed corporate culture that prioritized aggressive revenue growth over regulatory compliance and clinical quality.

A closer look at the financial trajectory of DaVita Inc. and Tenet Healthcare Corporation rounds out the comparison.

DaVita Inc.: DaVita reported 2025 revenue of $13.643 billion (up 6.5% from $12.816 billion in 2024), operating income of $2.044 billion, and net income attributable to DaVita of $747 million. Adjusted diluted EPS from continuing operations was $10.78. Operating cash flow was $1.887 billion and free cash flow $1.024 billion, and the company repurchased 12.7 million shares at an average $140.09. In Q2 2026 revenue reached $3.554 billion, operating income $579 million (16.3% margin), and diluted EPS $4.02. DaVita guides to 2026 adjusted EPS of $14.10 to $15.20 and free cash flow of $1.0 to $1.25 billion. It pays no dividend and returns cash through buybacks.

Tenet Healthcare Corporation: Tenet Healthcare reported 2025 net operating revenues of $21.31 billion, up 3.1% from $20.675 billion in 2024, with consolidated adjusted EBITDA of $4.566 billion (21.4% margin). Net income available to common shareholders was $1.407 billion ($15.49 per diluted share), versus $3.2 billion in 2024, when results were inflated by gains on hospital divestitures. Momentum continued in 2026: second-quarter revenue rose 6.8% to $5.628 billion, adjusted EBITDA grew 16.3% to $1.304 billion (23.2% margin), and hospital-segment EBITDA margin improved to 18.0%. Management raised 2026 guidance to $21.9-$22.5 billion of revenue and $4.83-$5.03 billion of adjusted EBITDA, and the board added $2.0 billion to the share buyback authorization.